AXONIS Therapeutics Announces $5 Million in Funding; Provides Update on Progress Advancing Novel Therapeutics for Neurological Disorders

15 Jul, 2021

AXONIS Therapeutics Announces $5 Million in Funding; Provides Update on Progress Advancing Novel Therapeutics for Neurological Disorders
Photo by rupixen.com on Unsplash

– AXONIS secured an additional $5m in funding.
– The round was led by Alexandria Venture Investments with participation by R3 Bio, BoxOne Ventures and Civilization Ventures and two leading spinal cord injury non-profit foundations, the Christopher & Dana Reeve Foundation and Spinal Research.
– The new investment will support AXONIS’ next development phase as it continues to advance its novel neuromodulating technology into the clinic.
– The Company’s pipeline includes neuron-reviving therapeutics that enable an intrinsic ability of central nervous system (CNS) neurons to resist degeneration, restore excitation/inhibition balance and regenerate.
– The Company’s targeted indications include spinal cord injury and epilepsy, as well as broader neurodegenerative conditions.

Biotechnology Medical North America
Crunchbase icon

Content report

The following text will be sent to our editors: